Thyrocare To Exit Radiology, Sell Nueclear For Rs 141 Cr

Thyrocare Technologies’ board has approved selling its entire stake in radiology subsidiary Nueclear Healthcare to Trovera Healthcare for about ₹141.4 crore, as the diagnostics company exits imaging to focus on its core pathology business.

The Deal: What Thyrocare Is Selling

Thyrocare Technologies‘ board, at a meeting on 21 September 2026, approved the sale of its entire 100% stake in wholly owned subsidiary Nueclear Healthcare Limited (NHL) 1,11,11,000 equity shares to Trovera Healthcare Private Limited.

The total consideration works out to about ₹141.40 crore, made up of roughly ₹81.90 crore in cash and ₹59.50 crore through 42,500 compulsorily convertible preference shares (CCPS) of Trovera, priced at ₹14,000 per CCPS.

The CCPS allotment gives Thyrocare a 4.5% equity stake in Trovera on a fully diluted basis, according to the company’s disclosure.

A Property Purchase Runs Alongside The Sale

Separately, Thyrocare will buy back the Gurugram and Hyderabad properties it currently rents from Nueclear Healthcare, for about ₹20.59 crore, to keep using them as diagnostic laboratory premises without disruption.

Both the sale of NHL and the property purchase still need approval from Thyrocare’s shareholders and other regulatory clearances, and the deal is expected to close by 30 November 2026.

Why Thyrocare Is Exiting Radiology

Nueclear Healthcare runs Thyrocare’s radiology and diagnostic-imaging business, which is more capital-intensive than its main pathology testing operations. Nueclear contributed ₹44.62 crore, or 5.38%, of Thyrocare’s consolidated turnover in FY26.

By exiting radiology, Thyrocare said it wants to redirect capital and management attention toward its core, less capital-heavy pathology business.

What This Means For Shareholders

This is a corporate restructuring, not an earnings announcement the deal changes what Thyrocare owns rather than how much it currently earns from testing services.

Shareholders will get to vote on the NHL sale, and investors tracking the outcome will need to watch for the shareholder meeting date and any updates once regulatory approvals come through.

To buy, hold or track Thyrocare shares through this process, investors need an active demat account and trading account, ideally on a trading platform that flags corporate-action updates such as board resolutions and shareholder votes.

Investments in the securities market are subject to market risks. This article is for informational purposes only and is not investment advice.